Pursuant to the provisions of regulation 30 of the Listing Regulations, Zydus Lifesciences has informed that the Company and Zydus Pharmaceuticals USA, Inc., USA, a wholly owned subsidiary, (together referred to as ‘Zydus’), have entered into a Settlement Agreement with Astellas in relation to Astellas’ Myrbetriq® (generic name: Mirabegron). This development is in continuation of its earlier intimation dated April 17, 2025, regarding the US patent litigation with Astellas. Under the terms of the Settlement Agreement: 1. Zydus shall pay Astellas an aggregate amount of USD 120 million. 2. Zydus shall additionally pay a prepaid per unit licensing fee on units of Zydus’ generic Mirabegron sold in the US from the date of Settlement Agreement till September 2027. Other terms and conditions of the Settlement Agreement remain confidential. This Settlement Agreement concludes all litigations between Astellas and the two companies relating to Myrbetriq® and Mirabegron and enables Zydus to continue marketing its generic Mirabegron in the US.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1824.10 |
| Dr. Reddys Lab | 1287.95 |
| Cipla | 1334.85 |
| Zydus Lifesciences | 901.65 |
| Lupin | 2350.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: